Atomoxetine (Strattera) is the most widely prescribed non-stimulant ADHD medication, but it doesn't work for everyone. If you've been taking it and aren't seeing the focus, attention, or impulse control improvements you expected, you're far from alone. The reasons range from simple timing issues to something built into your DNA.
Contact your doctor immediately if you experience chest pain, rapid or irregular heartbeat, difficulty breathing, or thoughts of self-harm. While rare, atomoxetine can affect cardiovascular function and mood, particularly during dose changes.
Unlike Adderall or Ritalin, which can work within hours, atomoxetine needs weeks to build up in your system. Full effects often take 4 to 6 weeks, and some people don't see the maximum benefit until 8 to 12 weeks. If you switched from a stimulant, the slower onset can feel like nothing is happening.
Atomoxetine is typically started at 40 mg/day and can be increased to 80 mg or even 100 mg. Many people are underdosed because the titration was too conservative or stopped too early. Your doctor may need to push the dose higher before concluding the drug doesn't work.
Atomoxetine works differently than stimulants. It doesn't produce the immediate, noticeable 'switch-on' effect. Instead, it provides a more gradual improvement in sustained attention and emotional regulation. Some people don't recognize the improvement until they look back over several weeks.
Common side effects like nausea, decreased appetite, and fatigue can be most pronounced during the first few weeks, exactly when you're trying to judge whether the medication is helping. These typically improve with time, but they can make it hard to evaluate efficacy early on.
Atomoxetine has one of the strongest genetic connections of any ADHD medication. Over 40% of people carry genetic variations that meaningfully affect how their body processes this drug.
CYP2D6 is the liver enzyme primarily responsible for metabolizing atomoxetine. This gene is highly variable across the population. Some people have extra copies that make the enzyme work overtime (ultrarapid metabolizers), while others have variants that severely reduce or eliminate enzyme activity (poor metabolizers). About 5-10% of Caucasians are poor metabolizers, and 1-2% are ultrarapid metabolizers.
If you're an ultrarapid metabolizer, your body may clear atomoxetine so quickly that standard doses never build up to therapeutic levels. This is one of the most common genetic reasons the drug appears to 'not work.' At the other extreme, poor metabolizers break down atomoxetine very slowly, leading to much higher blood levels. This can mean more side effects (increased heart rate, elevated blood pressure, insomnia), but paradoxically may also mean better ADHD symptom control for those who can tolerate the higher levels. CPIC guidelines recommend plasma concentration monitoring and dose adjustments based on metabolizer status.
Pharmacogenetic testing is particularly valuable for atomoxetine because CYP2D6 status has such a large impact on drug levels. If you've tried an adequate dose for at least 6 weeks without improvement, or if you're experiencing significant side effects even at low doses, testing can tell you whether your metabolism is the problem. This information can help your doctor either adjust the dose or decide that a different medication class is a better fit.
Learn how genetics may affect your response to these related medications:
Atomoxetine is a norepinephrine reuptake inhibitor, not a stimulant. It works by increasing norepinephrine levels in the brain rather than dopamine. It takes longer to work (weeks vs. hours) but provides 24-hour coverage without the abuse potential of stimulants.
It means your liver enzyme CYP2D6 works much slower than average at breaking down certain drugs, including atomoxetine. This leads to higher drug levels in your blood, which can mean more side effects. About 5-10% of people of European descent are poor metabolizers.
Some doctors do prescribe atomoxetine alongside stimulants, but this should only be done under careful medical supervision. The combination affects different neurotransmitter systems, which may provide complementary benefits but also increases the risk of cardiovascular side effects.
Find out how your DNA may influence your response to Atomoxetine and other medications with a Gene2Rx pharmacogenetics report.
Get Your Report Try Our Free Calculator